Adaptive Biotechnologies

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Adaptive Biotechnologies reports robust Q4 performance and eyes growth opportunities

Adaptive Biotechnologies delivered strong financial performance in Q4 2022 and full-year 2022, driven by growth in MRD and immune medicine segments, showcasing operational efficiency and revenue expansion.
While facing challenges such as paused T-Detect commercialization and revenue phasing complexities, the company is well-positioned to capitalize on opportunities like market acceptance of MRD and drug discovery partnerships.
With a positive revenue outlook for 2023, supported by strategic initiatives and a strong cash position, Adaptive Biotechnologies is poised for continued growth and market leadership in the biotechnology sector.

Adaptive Biotechnologies reports robust Q1 revenue and growth prospects

Adaptive Biotechnologies showcased strong revenue growth and operational improvements in Q1 2023.
The company is strategically positioned to capitalize on opportunities in MRD business and immune medicine segment.
Challenges include potential impacts from regulatory changes and the need for milestone achievements.
Overall, Adaptive Biotechnologies remains focused on growth, innovation, and expanding its market presence.

Adaptive Biotechnologies reports revenue growth and strategic partnerships in Q2

Adaptive Biotechnologies demonstrated solid revenue growth and margin improvement in Q2 2023, with a strategic outlook for future profitability.
Strong partnerships with Genentech and advocacy for MRD as a clinical endpoint position the company for continued success in the market.
Ongoing challenges in pricing and integration efforts are being addressed, while opportunities in drug discovery and AI-driven target discovery offer growth potential.

Adaptive Biotechnologies reports Q3 revenue growth amidst industry challenges

Adaptive Biotechnologies saw mixed performance with MRD growth and Immune Medicine decline.
Company's focus on MRD profitability and novel target identification shows strategic strength.
Facing challenges from industry softening and cost pressures but eyeing revenue growth opportunities.
Maintaining long-term target of $1,600 in 2027 while making progress towards profitability.

Adaptive Biotechnologies reports mixed Q4 results, focuses on MRD growth

Adaptive Biotechnologies navigated a transformative year in 2023, with a strong focus on MRD and Immune Medicine businesses. The company faces challenges in Immune Medicine revenue decline and achieving profitability. Strategic initiatives and partnerships position the company for growth and innovation in the biotechnology sector.

Adaptive Biotechnologies posts solid Q1 results, eyes breakeven targets

Adaptive Biotechnologies reported strong MRD revenue growth and aims to reduce operating expenses significantly in 2024. Despite a net loss, the company updated full-year guidance with a focus on achieving breakeven targets by 2025 and 2026. Opportunities lie in MRD segment expansion and immune medicine development.

Adaptive Biotechnologies excels in Q3 2024, eyes growth opportunities

Adaptive Biotechnologies delivered a robust performance in Q3 2024, marked by revenue growth, cost efficiencies, and strategic advancements in key segments.
While facing challenges in maintaining growth and profitability, the company's focus on operational excellence and innovation positions it well for future success.
With upcoming product launches and continued R&D efforts, Adaptive Biotechnologies is poised to capitalize on opportunities for market expansion and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.

SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2022.

Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results

Adaptive Biotechnologies (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Adaptive Biotechnologies (ADPT) This Earnings Season?

clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in DLBCL clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in DLBCL

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: Should You Buy?

Beam Therapeutics

Novavax

Vertex Pharmaceuticals

Check these health care stocks out for your watchlist right now

Top Health Care Stocks To Buy Right Now? 4 To Watch

SEATTLE, July 08, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 3, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

Adaptive Biotechnologies Corp (NASDAQ: ADPT) shares are trading higher by 12.58% to $7.25 after the company launched T-Detect Lyme, to help diagnose early lyme disease. Adaptive Biotechnologies says, in a clinical validation study among patients with early Lyme disease, the T-cell test was.

Why Adaptive Biotechnologies Shares Are Rising

Adaptive Biotechnologies unveiled a new type of test Wednesday for Lyme disease that may be most useful at detecting disease during the early stages of infection.

Adaptive Biotechnologies launches T cell-based test for Lyme disease

T-Detect Lyme enables patients and healthcare providers to detect early Lyme disease with greater sensitivity than leading antibody tests T-Detect Lyme enables patients and healthcare providers to detect early Lyme disease with greater sensitivity than leading antibody tests

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

Data demonstrate growing utilization of MRD to identify deep responses associated with the best patient outcomes Data demonstrate growing utilization of MRD to identify deep responses associated with the best patient outcomes

Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment Technology

BridgeBio Pharma Inc

Ginkgo Bioworks Holdings

FuboTV

Himax Tech

Microsoft

Because of this stock market crash, some wonderful stocks are super cheap in 2022. Here's a mini-portfolio of innovative companies trading under $10 a share right now.

10 Amazing Stocks Under $10 (Part II)

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -2.33% and 0.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Lags Revenue Estimates

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Chief Executive Officer and Co-Founder Kyle Piskel - Interim Chief Financial Officer Sharon Benzeno - Chief Commercial Officer, Immune Medicine Nitin Sood - Chief Commercial Officer, MRD Harlan Robins - Chief Scientific Officer Conference Call Participants Brian Weinstein - William Blair Elizabeth Webster - Goldman Sachs Mark Massaro - BTIG Derik de Bruin - Bank of America Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio should the corresponding text be unclear.

Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q1 2022 Results - Earnings Call Transcript

Adaptive Biotechnologies announced its first quarter earnings Wednesday, two months after laying off 12% of its workforce.

Adaptive Biotechnologies reports $38.6M in Q1 revenue as it repositions following job cuts

SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2022.

Adaptive Biotechnologies Reports First Quarter 2022 Financial Results

SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada.

Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference

Adaptive Biotech product 'clonoSEQ' is the first MRD test cleared by FDA for multiple myeloma, CLL, and B-ALL. The company's "T-Detect" is the first-ever T Cell-Based Diagnostic Test.

Adaptive Biotechnologies: Becoming The Next Big Thing In The Biotech Industry

Adaptive Biotechnologies sports a market-leading advantage with its one-of-a-kind proprietary tech. The company's stock has been smashed in the last year losing over two-thirds of its share price.

Adaptive Biotechnologies: Good Buy For Long-Term Investors

SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 4, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022

Burning Rock Biotech

The CEO of Ark Invest hasn't given up on these risky biotech stocks.

Cathie Wood Can't Get Enough of These 2 Biotech Stocks

Adaptive Biotechnologies (ADPT) announces reorganization of its business around MRD and Immune Medicine to drive future growth. The company hires a market veteran in health care as its new CFO.

Adaptive Biotechnologies (ADPT) Rises on Restructuring Plans

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) will be organized around two distinct business areas - Minimal Residual Disease (MRD) and Immune Medicine. Adaptive's MRD business includes clonoSEQ diagnostic tests for clinicians and the clonoSEQ assay for pharmaceutical partners to.

Adaptive Biotechnologies To Lay Off ~12% Of Its Workforce, Names Tycho Peterson As CFO

The company reiterates full year 2022 guidance The company reiterates full year 2022 guidance

Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

Adaptive Biotechnologies is laying off 12% of its workforce, or about 100 employees, GeekWire has learned.

Adaptive Biotechnologies lays off about 100 people, 12% of headcount, to ‘streamline our workforce'

SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the upcoming 42nd Annual Cowen Healthcare Conference.

News for Adaptive Biotechnologies Stock (ADPT)